EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine

Bing Li, Yuanjun Tang, Zhanya Huang, Lijun Ma iD, Jiagui Song iD, Lixiang Xue iD

Protein & Cell · 01.08.2026 · 17 (8) · 686-703

DOI: 10.1093/procel/pwaf058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Protein & Cell, online erschienen am 13.07.2025. Verfasst von Bing Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center of Peking University Third Hospital, Beijing 100191, China. Hauptthemen laut MEDLINE: Precision Medicine, Organoids, Lab-On-A-Chip Devices, Drug Development. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, General Program of the National Natural Science Foundation of China, Youth Program of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FDA issued guidance on 10 April 2025 to phase out animal trials in favor of organoids and organ-on-a-chip systems. This pivotal move was swiftly followed by the National Institutes of Health (NIH) on April 29th, when it inaugurated the Office of Research Innovation, Validation, and Application (ORIVA). The establishment of ORIVA aims to spearhead the advancement of human-centric organ-on-a-chip technologies, marking a major stride toward more accurate, ethical, and efficient research methods in the biomedical field. Compared to traditional 2D cell cultures and animal models, organ-on-a-chip systems enable precise control of hydrodynamic parameters and biomechanical microenvironments. This review systematically elaborates on applications of single-organ, multi-organ, and organoid-on-a-chip technologies in modeling complex diseases, host–microbiome interactions, inter-organ physiological networks, and quantitative prediction of pharmacokinetics, toxicity responses, and personalized therapies. Furthermore, the core challenges in translating these technologies to pharmaceutical development and clinical practice are critically analyzed. With interdisciplinary integration of materials engineering, biosensing, and artificial intelligence, organ-on-a-chip technologies are transcending the limitations of conventional preclinical research. Their strategic value as "patient surrogates" is poised to accelerate breakthroughs in precision medicine and rare disease treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineOrganoidsLab-On-A-Chip DevicesDrug DevelopmentModels, BiologicalHumansAnimalsMicrophysiological Systems

Stichwörter der Autor:innen

animal trial alternativesdisease modelingmicrophysiological systemsorgan-on-a-chiporganoidsprecision medicine

Autor:innen und Institutionen

  • Cancer Center of Peking University Third Hospital, Beijing 100191, China.
  • Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China.
  • Peking Key Laboratory of Interdisciplinary Research in Gastrointestinal Oncology (BLGO), Peking University Third Hospital, Beijing 100191, China.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.

ORCID-Profile: Lijun Ma, Jiagui Song, Lixiang Xue

Förderung

  • National Key Research and Development Program of China
  • General Program of the National Natural Science Foundation of China
  • Youth Program of the National Natural Science Foundation of China
  • Peking University Third Hospital Clinical Key Project
  • Peking University Medicine plus X Pilot Program-Platform Construction Project
  • Key Research Project of Ningxia Natural Science Foundation
  • Project of Ningxia Natural Science Foundation
  • Scientific Research Project of Ningxia Medical University

Zitieren

APA

Li, B., Tang, Y., Huang, Z., Ma, L., Song, J., & Xue, L. (2026). Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine. Protein & Cell, 17(8), 686-703. https://doi.org/10.1093/procel/pwaf058

Vancouver

Li B, Tang Y, Huang Z, Ma L, Song J, Xue L. Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine. Protein & Cell. 2026;17(8):686-703. doi:10.1093/procel/pwaf058

BibTeX
@article{Li2026,
  author = {Li, Bing and Tang, Yuanjun and Huang, Zhanya and Ma, Lijun and Song, Jiagui and Xue, Lixiang},
  title = {Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine},
  journal = {Protein & Cell},
  year = {2026},
  volume = {17},
  number = {8},
  pages = {686--703},
  doi = {10.1093/procel/pwaf058}
}
Kostenlos starten →